The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia
Abstract
All transretinoic acid (ATRA) followed by daunorubicin (DNR)-AraC chemotherapy (CT) has improved the outcome of acute promyelocytic leukemia (APL) by comparison to CT alone. In a randomized trial, (1) we compared 2 induction schedules (ATRA followed by CT [ATRA→CT] and ATRA plus CT [ATRA+CT, with CT added on day 3 of ATRA treatment]) and (2) we assessed the role of maintenance treatment. Four hundred thirteen patients ≤75 years of age and with newly diagnosed APL were included. Induction treatment was stratified on white blood cell (WBC) count and age: patients ≤65 years of age and with an initial WBC count of ≤5,000/μL (n = 208) were randomized between ATRA→CT and ATRA+CT (initially randomized patients); patients with a WBC count greater than (high WBC count group, n = 163) and patients 66 to 75 years of age with a WBC count greater than 5,000/μL (elderly group, n = 42) were not initially randomized and received ATRA+CT from day 1 and ATRA →CT, respectively. All patients achieving CR received 2 additional DNR-AraC courses (only 1 in patients 66 to 75 years of age) and were then randomized for maintenance between no treatment, intermittent ATRA (15 days every 3 months) for 2 years, continuous low-dose CT (6 mercaptopurine + methotrexate) for 2 years, or both, using a 2-by-2 factorial design. Overall, 381 (92%) of the patients achieved complete remission (CR), 31 (7%) suffered an early death, and only 1 patient had leukemic resistance. ATRA syndrome occurred in 64 patients (15%) and was fatal in 5 cases. The CR rate was similar in all induction treatment groups. Event-free survival (EFS) was significantly lower in the high WBC group (P = .0002) and close to significance in the elderly group (P = .086) as compared with initially randomized patients. Relapse at 2 years was estimated at 6% in the ATRA+CT group, versus 16% in the ATRA→CT group (P = .04, relative risk [RR] = .41). EFS at 2 years was estimated at 84% in the ATRA+CT group, versus 77% in the ATRA→CT group (P = .1, RR = .62). Two hundred eighty-nine patients were randomized for maintenance. The 2-year relapse rate was 11% in patients randomized to continuous maintenance CT and 27% in patients randomized to no CT (P = .0002) and 13% in patients randomized to intermittent ATRA and 25% in patients randomized to no ATRA (P= .02). An additive effect of continuous maintenance CT and intermittent ATRA was seen, and only 6 of the 74 patients who received both maintenance treatments had relapsed. Overall survival was improved in patients who received maintenance CT (P = .01), and there was a trend for better survival in patients who received maintenance ATRA (P = .22). Our findings strongly suggest that early addition of chemotherapy to ATRA and maintenance therapy combining continuous CT and intermittent ATRA can reduce the incidence of relapse in APL. This effect already translates into significantly better survival for maintenance treatment with continuous CT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
Huang, M., Ye, Y., Chen, Sr., Chai, Jr., Lu, J., Zhoa, L., Gu, L., & Wang, Z. (1988) · Blood · doi:10.1182/blood.v72.2.567.567 · Cited by 2,445
Kakizuka, A., Miller, W. H., Umesono, K., Warrell, R. P., Frankel, S. R., Murty, V. V. V. S., Dmitrovsky, E., & Evans, R. M. (1991) · Cell · doi:10.1016/0092-8674(91)90112-c · Cited by 1,427
de Thé, H., Lavau, C., Marchio, A., Chomienne, C., Degos, L., & Dejean, A. (1991) · Cell · doi:10.1016/0092-8674(91)90113-d · Cited by 1,343
Self-citationDifferentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)
Warrell, R. P., Frankel, S. R., Miller, W. H., Scheinberg, D. A., Itri, L. M., Hittelman, W. N., Vyas, R., Andreeff, M., Tafuri, A., Jakubowski, A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199105163242002 · Cited by 1,251
Castaigne, S., Chomienne, C., Daniel, M., Ballerini, P., Berger, R., Fenaux, P., & Degos, L. (1990) · Blood · doi:10.1182/blood.v76.9.1704.1704 · Cited by 1,184
Self-citationAll-trans-Retinoic Acid in Acute Promyelocytic Leukemia
Tallman, M. S., Andersen, J. W., Schiffer, C. A., Appelbaum, F. R., Feusner, J. H., Ogden, A., Shepherd, L., Willman, C., Bloomfield, C. D., Rowe, J. M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371501 · Cited by 1,073
The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia
Frankel, S. R., Eardley, A., Lauwers, G., Weiss, M., & Warrell, R. P. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-4-292 · Cited by 705
Fenaux, P., Le Deley, M., Castaigne, S., Archimbaud, E., Chomienne, C., Link, H., Guerci, A., Duarte, M., Daniel, M., & Bowen, D. (1993) · Blood · doi:10.1182/blood.v82.11.3241.3241 · Cited by 516
Self-citationMandelli, F., Diverio, D., Avvisati, G., Luciano, A., Barbui, T., Bernasconi, C., Broccia, G., Cerri, R., Falda, M., Fioritoni, G., et al. (1997) · PubMed · doi:10.1182/blood.v90.3.1014 · Cited by 474
Evidence for a 15; 17 translocation in every patient with acute promyelocytic leukemia
Larson, R. A., Kondo, K., Vardiman, J. W., Butler, A. E., Golomb, H. M., & Rowley, J. D. (1984) · The American Journal of Medicine · doi:10.1016/0002-9343(84)90994-x · Cited by 417
Muindi, J., Frankel, Sr., Miller, W. J., Jakubowski, A., Scheinberg, D., Young, C., Dmitrovsky, E., & Warrell, R. J. (1992) · Blood · doi:10.1182/blood.v79.2.299.bloodjournal792299 · Cited by 408
Chen, Z., Xue, Y., Zhang, R., Tao, R., Xia, X., Li, C., Wang, W., Zu, W., Yao, X., & Ling, B. (1991) · Blood · doi:10.1182/blood.v78.6.1413.1413 · Cited by 399
Chomienne, C., Ballerini, P., Balitrand, N., Daniel, M., Fenaux, P., Castaigne, S., & Degos, L. (1990) · Blood · doi:10.1182/blood.v76.9.1710.1710 · Cited by 375
Self-citationDe Botton, S., Dombret, H., Sanz, M., Miguel, J. S., Caillot, D., Zittoun, R., Gardembas, M., Stamatoulas, A., Condé, E., Guerci, A., et al. (1998) · Blood · doi:10.1182/blood.v92.8.2712 · Cited by 339
Self-citationMuindi, J., Frankel, Sr., Miller, W. J., Jakubowski, A., Scheinberg, D., Young, C., Dmitrovsky, E., & Warrell, R. J. (1992) · Blood · doi:10.1182/blood.v79.2.299.299 · Cited by 314
Asymptotically efficient rank invariant test procedure (with discussion).
Peto, R. (1972) · Medical Entomology and Zoology · Cited by 307
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-92-2-280_1 · Cited by 304
Vahdat, L., Maslak, P., Miller, W. J., Eardley, A., Heller, G., Scheinberg, D., & Warrell, R. J. (1994) · Blood · doi:10.1182/blood.v84.11.3843.bloodjournal84113843 · Cited by 296
Reassessing the hemostatic disorder associated with acute promyelocytic leukemia [see comments]
Tallman, M., & Kwaan, H. (1992) · Blood · doi:10.1182/blood.v79.3.543.543 · Cited by 293
All-trans Retinoic Acid for Acute Promyelocytic Leukemia: Results of the New York Study
Frankel, S. R., Eardley, A., Heller, G., Berman, E., Miller, W. H., Dmitrovsky, E., & Warrell, R. P. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-4-199402150-00004 · Cited by 262
Kanamaru, A., Takemoto, Y., Tanimoto, M., Murakami, H., Asou, N., Kobayashi, T., Kuriyama, K., Ohmoto, E., Sakamaki, H., & Tsubaki, K. (1995) · Blood · doi:10.1182/blood.v85.5.1202.bloodjournal8551202 · Cited by 234
Fenaux, P., Castaigne, S., Dombret, H., Archimbaud, E., Duarte, M., Morel, P., Lamy, T., Tilly, H., Guerci, A., & Maloisel, F. (1992) · Blood · doi:10.1182/blood.v80.9.2176.2176 · Cited by 232
Self-citationAcute promyelocytic leukemia: treatment results during a decade at Memorial Hospital
Cunningham, I., Gee, T., Reich, L., Kempin, S., Naval, A., & Clarkson, B. (1989) · Blood · doi:10.1182/blood.v73.5.1116.1116 · Cited by 196
Delva, L., Cornic, M., Balitrand, N., Guidez, F., Miclea, J., Delmer, A., Teillet, F., Fenaux, P., Castaigne, S., & Degos, L. (1993) · Blood · doi:10.1182/blood.v82.7.2175.2175 · Cited by 180
Self-citationRetinoic Acid Syndrome: Recognition, Prevention and Management
Fenaux, P., & De Botton, S. (1998) · Drug Safety · doi:10.2165/00002018-199818040-00003 · Cited by 173
Self-citationWarrell, R. P., Maslak, P. G., Eardley, A. M., Heller, G., Miller, W. H., & Frankel, S. (1994) · PubMed · Cited by 140
Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid
Degos, L., Chomienne, C., Daniel, M., Berger, R., Dombret, H., Fenaux, P., & Castaigné, S. (1990) · The Lancet · doi:10.1016/0140-6736(90)93135-c · Cited by 134
Self-citationA Variant Form of Hypergranular Promyelocytic Leukemia (M3)
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., GALTON, D. A. G., GRALNICK, H. R., SULTAN, C., & GRALNICK, H. R. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-92-2-261 · Cited by 97
All-Trans-Retinoic Acid Treatment for Patients with Acute Promyelocytic Leukemia
Degos, L., Chomienne, C., Daniel, M., Berger, R., & Castaigné, S. (2015) · KARGER eBooks · doi:10.1159/000420332 · Cited by 64
Self-citation[Acute promyelocytic leukemia: retrospective study of 119 patients treated with daunorubicin].
Marty, M. E., Ganem, G., Fischer, J., Flandrin, G., Berger, R., Schaison, G., Degos, L., & Boiron, M. (1984) · PubMed · Cited by 62
Self-citationPrognostic Factors in Acute Promyelocytic Leukemia: A Retrospective Study of 67 Cases
Thomas, X., Archimbaud, E., Treille, D., & Fiere, D. M. (1991) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199109068073 · Cited by 44
Self-citation
Cited by
Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,735
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,597
Sanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150250 · Cited by 947
Self-citationUnited States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3852 · Cited by 826
Metadata
- Authors
- Fenaux, P., Chastang, C., Chevret, S., Sanz, M., Dombret, H., Archimbaud, E., Fey, M., Rayon, C., Huguet, F., Sotto, J.-J., Gardin, C., Makhoul, P. C., Travade, P., Solary, E., Fegueux, N., Bordessoule, D., Miguel, J. S., Link, H., Desablens, B., Stamatoullas, A., Deconinck, E., Maloisel, F., Castaigne, S., Preudhomme, C., & Degos, L.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1999-08-15
- Volume
- 94
- Issue
- 4
- Pages
- 1192-1200
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1515269506
- Cited by
- 754
- References
- 36
- FWCI
- 14.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.